What Is Vyleesi?

Vyleesi is the proprietary name of an FDA-approved prescription drug-device combination product containing bremelanotide for subcutaneous injection. It is a specific finished product, not a general synonym for PT-141, bremelanotide acetate, compounded bremelanotide, or every research material labeled with a related peptide name.

Understanding this product-level distinction is part of the broader identity framework explained in PT-141 Peptide Research: Identity, Formulation, Evidence, and Regulatory Evaluation. Statements about Vyleesi should be tied to its official labeling and regulatory record rather than transferred to unrelated PT-141 or bremelanotide preparations.

Research-use notice: InStrips products are offered for research and analytical use only. They are not intended to diagnose, treat, cure, or prevent any disease, injury, deficiency, absorption disorder, digestive condition, or medical condition.

The existence of Vyleesi does not establish that a separately manufactured, compounded, or research-only PT-141 product has the same formulation, quality, approval, evidence, safety profile, or regulatory status.

Vyleesi Is a Brand Name

Vyleesi is a proprietary or brand name associated with a defined finished product.

A brand-product identity includes more than the name of the active substance.

It may include:

• active ingredient
• strength
• dosage form
• route
• device
• inactive ingredients
• manufacturer or labeler
• approved labeling

These attributes distinguish the product from bulk peptide material.

What Is the Active Ingredient?

The active ingredient in Vyleesi is bremelanotide.

Bremelanotide is the established substance name associated historically with the development code PT-141.

The active-substance name does not independently identify:

• the finished formulation
• the delivery presentation
• the manufacturer
• the approved indication
• the approved strength
• the complete product labeling

PT-141 and Vyleesi Are Different Naming Levels

PT-141 is a development and research name.

Bremelanotide is the active-substance name.

Vyleesi is the proprietary name of a finished drug product.

These terms correspond to different levels of identification:

• development compound
• active substance
• finished product

They should not be used as though they provide identical information.

Vyleesi Is a Drug-Device Combination Product

FDA review records describe Vyleesi as a drug-device combination product.

This means that the regulated product includes both:

• the drug formulation
• the delivery-device presentation

Product evaluation therefore includes attributes beyond the peptide substance alone.

Finished Product vs Bulk Peptide

Bulk bremelanotide or bremelanotide acetate is not the same as Vyleesi.

A finished product requires additional controls involving:

• formulation
• filling
• container closure
• device function
• sterility
• particulate matter
• stability
• labeling

The bulk-substance name does not establish completion of these steps.

Finished Product vs Research Material

A research material labeled PT-141 or bremelanotide may be intended for analytical or laboratory use.

It may differ from Vyleesi in:

• salt form
• concentration
• purity profile
• inactive ingredients
• container
• sterility status
• device
• regulatory oversight

Shared peptide terminology does not establish product equivalence.

Finished Product vs Compounded Preparation

A compounded bremelanotide preparation is not the FDA-approved Vyleesi product merely because both refer to the same active peptide.

Differences may involve:

• source of bulk substance
• formulation
• strength
• container
• manufacturing controls
• stability information
• regulatory category

Approval of Vyleesi does not transfer to a compounded preparation.

Dosage Form

Official FDA labeling identifies Vyleesi as a bremelanotide injection for subcutaneous use.

The dosage-form description is product specific and should not be assigned to every bremelanotide preparation.

Other materials may be supplied as:

• bulk powder
• lyophilized research material
• laboratory solution
• compounded preparation
• study-specific formulation

Subcutaneous Route

The approved product is labeled for subcutaneous administration.

Subcutaneous identifies placement into tissue beneath the skin.

This route should be distinguished from:

• intravenous administration
• intramuscular administration
• intranasal research
• oral formulations
• other experimental routes

Evidence from one route should not be transferred automatically to another.

Product Strength

FDA product records identify Vyleesi as containing 1.75 mg of bremelanotide in 0.3 mL.

This strength is an attribute of the approved finished product.

It should not be used to characterize:

• a research vial
• a bulk peptide powder
• a compounded product
• another concentration
• another delivery presentation

A product strength is not a universal property of the peptide.

Single-Dose Autoinjector Presentation

Official labeling describes Vyleesi as supplied in a single-dose autoinjector presentation.

The device contributes to the complete product identity through features involving:

• contained volume
• delivery mechanism
• needle system
• container closure
• device performance
• labeling

A vial of bremelanotide is not the same presentation.

Inactive Ingredients

A finished drug product contains inactive formulation components in addition to the active peptide.

These components can contribute to:

• pH control
• tonicity
• stability
• solubility
• container compatibility
• product performance

Statements about the complete formulation should come from official product information.

Bremelanotide Acetate and the Finished Product

Chemical and product records may describe bremelanotide acetate in connection with the active substance.

The acetate designation describes a molecular or salt-form relationship rather than the complete Vyleesi product.

Finished-product identity also requires:

• peptide amount
• complete excipient composition
• solution volume
• container and device
• manufacturing controls
• approved labeling

Vyleesi Is Not the Chemical Name

Vyleesi is a proprietary product name rather than the formal chemical or peptide name.

Chemical identity may be represented through:

• bremelanotide
• bremelanotide acetate
• molecular formula
• amino-acid sequence
• structural representation

A product name and chemical identity provide different information.

Vyleesi Is Not a General Peptide Category

The product name should not be used as a category label for:

• all melanocortin peptides
• all PT-141 materials
• all bremelanotide products
• all peptide injections
• all compounded peptides
• all products discussed in related research

It identifies one regulated product.

Vyleesi Is Not Melanotan II

Melanotan II is a separate peptide and should not be represented as the active ingredient in Vyleesi.

Confusing the terms can lead to errors involving:

• sequence identity
• product approval
• scientific literature
• risk information
• commercial product identification

Historical relationships do not create product equivalence.

FDA Approval Is Product Specific

FDA approval applies to the product described in the approved application and labeling.

The determination is linked to:

• the active ingredient
• formulation
• strength
• route
• device
• manufacturing process
• evidence package

Approval does not extend automatically to another preparation containing a similarly named peptide.

What the Approved Indication Means

The official label defines the population and condition for which the product was approved.

That indication belongs to Vyleesi under its labeled conditions and should not be broadened to:

• other populations
• other conditions
• other peptide products
• other formulations
• other routes
• research-only materials

This article does not convert the approved indication into personal-use guidance.

What the Label Does Not Establish for Other Products

Vyleesi labeling does not establish the identity, quality, or performance of a separately supplied PT-141 product.

It cannot be used to prove that another product has the same:

• active-substance content
• purity
• impurities
• sterility
• endotoxin status
• formulation
• stability
• device performance

Mechanism-of-Action Language

The official label discusses melanocortin-receptor activity and notes limits in understanding how that activity relates to the product’s clinical effect.

Mechanism language should be distinguished from:

• product identity
• clinical outcome measurements
• approved indication
• personal suitability
• comparisons with unrelated peptides

A receptor mechanism is not a product-quality test.

Clinical Studies Are Product Specific

The clinical evidence reviewed for approval involved a defined bremelanotide product, protocol, participant population, route, and outcome framework.

Those results should not be transferred automatically to:

• laboratory PT-141 powder
• compounded bremelanotide
• another strength
• another formulation
• another route
• Melanotan II

The studied product must remain visible in the interpretation.

Adverse-Reaction Information Is Also Product Specific

The official label describes adverse reactions and warnings identified through the Vyleesi development and review record.

This information should not be used to claim that an unrelated preparation has:

• the same impurity profile
• the same concentration
• the same formulation
• the same delivery pattern
• the same observed reaction frequency

Related active-substance names do not create complete safety equivalence.

Contraindications and Warnings Belong to the Label

Contraindications, warnings, and precautions are part of the official product labeling.

They apply to the regulated product and should be read in full rather than summarized selectively or transferred to another product without justification.

Research-only coverage should not transform labeling information into individualized medical advice.

Product Quality

FDA approval involves evaluation of product-quality information for the defined drug-device combination.

Quality attributes may include:

• active-substance identity
• assay
• impurities
• formulation
• sterility
• particulate matter
• container integrity
• stability
• device performance

These findings do not certify unrelated products.

Manufacturing Controls

A regulated finished product is associated with defined manufacturing and control information.

This may involve:

• qualified raw materials
• validated processes
• in-process controls
• release specifications
• stability programs
• change controls
• facility oversight

A commercial peptide listing does not demonstrate the same control system.

Sterility

Vyleesi is a finished injectable drug product subject to product-specific sterility requirements.

That does not mean every PT-141 or bremelanotide product is sterile.

Sterility must be supported for the specific:

• batch
• container
• manufacturing process
• test method
• holding period

Bacterial Endotoxins

Endotoxin control is separate from peptide identity and chromatographic purity.

A separately supplied peptide would require its own evidence concerning:

• test method
• interference controls
• acceptance limit
• batch result
• sample handling

Vyleesi’s approved status does not establish another product’s endotoxin status.

Particulate Matter

Injectable finished products require evaluation of visible and subvisible particulate matter.

Particles may arise from:

• peptide aggregation
• excipient precipitation
• container surfaces
• device components
• manufacturing processes

Particulate quality is batch and product specific.

Stability

The approved product has storage and stability information tied to its formulation and presentation.

Those data do not determine the stability of:

• bulk bremelanotide
• lyophilized PT-141
• a compounded solution
• another container
• another concentration
• another salt composition

Manufacturer and Labeler Information

Manufacturer, distributor, or labeler information can change over a product’s commercial history.

Current product identification should therefore use:

• current official labeling
• current National Drug Code information
• current DailyMed records
• current manufacturer or labeler records

An old webpage may not reflect the current commercial presentation.

Product Name Does Not Identify Every Package

A proprietary name can appear on more than one package size or National Drug Code entry.

Package-level identification may require:

• NDC
• package quantity
• device count
• labeler
• lot number
• expiration date

These details are separate from the active-substance name.

Vyleesi and Generic Terminology

The brand name Vyleesi should be distinguished from the general substance name bremelanotide.

A page discussing bremelanotide may concern:

• the active substance generally
• the approved product
• a clinical-study product
• a chemical standard
• a compounded preparation
• a laboratory material

The source must state which level applies.

Vyleesi and PT-141 Search Language

Search results may use Vyleesi, bremelanotide, and PT-141 together.

This can be useful for explaining naming history, but it can also blur distinctions between:

• development code
• active substance
• salt form
• finished product
• research listing

Each term should be defined before evidence is discussed.

The Product Does Not Validate Every PT-141 Claim

The existence of an approved bremelanotide product does not validate online claims about every PT-141 product or proposed use.

Claims should be checked for:

• product identity
• approved labeling
• population
• route
• study design
• source quality
• regulatory context

Approval should not be used as a category-wide endorsement.

Vyleesi Is Not Evidence That Peptide Products Are Interchangeable

A named approved product demonstrates the importance of product-specific evaluation.

It does not establish interchangeability with a product that differs in:

• manufacturer
• salt form
• formulation
• strength
• device
• route
• quality documentation

Vyleesi Does Not Identify Research-Only InStrips Products

InStrips products are described for research and analytical use only.

The discussion of Vyleesi in this article is included to clarify terminology and product distinctions.

It does not imply that an InStrips material:

• is Vyleesi
• is equivalent to Vyleesi
• has the same formulation
• has the same regulatory status
• is intended for the approved use

Questions to Ask When a Source Mentions Vyleesi

Readers should ask:

• Is the source discussing the finished product?
• Is it discussing bremelanotide generally?
• Is the official label being cited?
• Is the statement limited to the approved indication?
• Is the formulation identified?
• Is another PT-141 product being treated as equivalent?
• Is the source current?

These questions prevent product-specific information from becoming a broad peptide claim.

Relationship to PT-141 Product Naming

Vyleesi demonstrates why a development name, active-substance name, salt name, and finished-product name should be kept separate.

The remaining limitations of the PT-141 name are explained in Why the Name PT-141 Does Not Fully Identify a Product.

Reading the Official Product Label

The DailyMed label record for Vyleesi provides official product information concerning the active ingredient, subcutaneous dosage form, presentation, labeling, warnings, and approved use.

The label concerns the defined Vyleesi product and should not be used to characterize or validate an unrelated PT-141, bremelanotide, compounded, or research-only preparation.

Final Perspective

Vyleesi is a specific FDA-approved prescription drug-device combination product containing bremelanotide for subcutaneous injection.

Vyleesi is not a general synonym for PT-141, bremelanotide acetate, Melanotan II, compounded bremelanotide, or research peptide materials.

Accurate research-only coverage should keep the development name, active-substance name, salt form, finished product, formulation, evidence, and regulatory status separate without transferring Vyleesi’s approval or product findings to unrelated materials.